A large-scale, eight‑year follow‑up study has demonstrated that a highly precise form of radiotherapy can deliver cancer control rates on par with traditional prostate removal surgery, while markedly reducing urinary side effects for men with low‑to‑intermediate risk disease. The findings, presented at the 2026 American Society for Radiation Oncology Annual Meeting, are expected to influence treatment guidelines and give patients a clearer, evidence‑based pathway when deciding between surgery and non‑invasive options.
New Evidence from the 2026 ASRO Meeting
Researchers from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, tracked 123 participants for an average of eight years. Half of the cohort underwent radical prostatectomy, a procedure that removes the entire prostate and carries known risks of erectile dysfunction and urinary incontinence. The other half received stereotactic body radiotherapy (SBRT), delivered in five sessions over one to two weeks, often using the CyberKnife system, which employs real‑time imaging to focus high‑dose radiation precisely on the tumour while sparing surrounding tissue. The study’s lead investigator, Professor Nicholas van As, emphasised that the trial was designed to fill a long‑standing gap in randomised data comparing long‑term oncological outcomes.
How the Treatment Works
SBRT represents a subset of external beam radiotherapy that concentrates multiple high‑dose fractions into the prostate with sub‑millimetre accuracy. The CyberKnife platform continuously monitors the tumour’s position via image‑guided technology, adjusting the beam in real time to maintain precision even if the prostate moves during breathing. This “non‑invasive knife” approach aims to eradicate cancer cells while minimising damage to adjacent organs such as the bladder and urethra, thereby preserving urinary and sexual function.
Patient Outcomes and Quality of Life
After eight years, 91.2 % of men treated with SBRT remained free from biochemical recurrence, compared with 83.7 % of those who had surgery. Recurrence events were recorded in five patients in the radiotherapy arm and eight in the surgical arm. Importantly, the side‑effect profiles diverged sharply: only 8.3 % of the SBRT group reported needing a daily urinary pad, whereas nearly half (48 %) of the prostatectomy patients relied on pads each day. The authors concluded that SBRT offers a viable, non‑surgical alternative with comparable disease control and a substantially lower impact on daily urinary function.
Implications for Clinical Practice
The trial’s results are likely to prompt a reassessment of current prostate‑cancer treatment algorithms, particularly for patients whose primary concern is preserving urinary and sexual health. Clinicians may now feel more confident recommending SBRT as a first‑line option for low‑to‑intermediate risk cases, provided that appropriate patient selection and access to advanced radiotherapy technology are in place. The data also underscore the value of long‑term follow‑up in evaluating emerging oncology therapies, ensuring that efficacy does not come at the expense of quality of life.
Why it Matters
This research marks a pivotal shift toward personalised, patient‑centred oncology care. By demonstrating that a precise, non‑invasive radiotherapy regimen can match the durability of surgery while sparing patients from common post‑operative complications, the study empowers men with prostate cancer to make informed choices that align with their lifestyle priorities. Moreover, the findings may reduce the overall burden on healthcare systems by lowering rates of post‑treatment incontinence and associated care costs, heralding a broader impact on how prostate cancer is managed worldwide.
